Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
Crossref DOI link: https://doi.org/10.1007/s12325-021-01989-z
Published Online: 2021-12-09
Published Print: 2022-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rao, Shaline
Funding for this research was provided by:
AstraZeneca
Text and Data Mining valid from 2021-12-09
Version of Record valid from 2021-12-09
Article History
Received: 22 September 2021
Accepted: 5 November 2021
First Online: 9 December 2021